|[March 22, 2013]
ACT's Chief Scientific Officer Dr. Robert Lanza to Deliver the Nerem Lecture 2013 at the 17th Annual Hilton Head Workshop
MARLBOROUGH, Mass. --(Business Wire)--
Advanced Cell Technology, Inc. ("ACT"; OTCBB:
ACTC), a leader in the field of regenerative medicine, announced
today that its chief scientific officer, Robert Lanza, M.D., will be
delivering the "Robert M. Nerem Lecture" at the 17th Annual Hilton
Head Workshop, "Regenerative Medicine: Technologies Enabling Novel
Therapies" being held on Hilton Head Island, March 20-23. The goal of
the workshop is to bring the community together in an intimate,
"Gordon-conference style" forum to share the latest insights and
discoveries in this rapidly progressing field. Dr. Lanza's Lecture,
entitled "The Use of Pluripotent Stem Cells in Regenerative Medicine,"
will take place on Saturday, March 23, at 5:00p.m. EDT.
Dr. Lanza's presentation is the second annual Nerem Lecture, with the
first having been delivered last year by George Q. Daley, M.D., Ph.D.
Samuel E. Lux IV Professor of Hematology/Oncology and Director of the
Stem Cell Transplantation Program at Children's Hospita Boston, and
Professor at Harvard Medical School.
The conference brings together leading researchers in the field of
regenerative medicine, along with other scientists, engineers, and
clinicians, including speakers from Harvard University, Stanford,
Cornell, Duke, UCLA, and the University of Pennsylvania, among others.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying
cellular technology in the field of regenerative medicine. For more
information, visit www.advancedcell.com.
Statements in this news release regarding future financial and
operating results, future growth in research and development programs,
potential applications of our technology, opportunities for the company
and any other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not statements of historical
fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions)
should also be considered to be forward-looking statements. There are a
number of important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for future
capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and
economic conditions generally. Additional information on potential
factors that could affect our results and other risks and uncertainties
are detailed from time to time in the company's periodic reports,
including the report on Form 10-K for the year ended December 31, 2012.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made, and
the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the
time they are made, and the company does not assume any obligation to
update its forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. There can be no
assurance that the Company's clinical trials will be successful.
[ Back To Technology News's Homepage ]